45 related articles for article (PubMed ID: 18813832)
1. Docetaxel treatment in the elderly patient with hormone refractory prostate cancer.
Sinibaldi VJ
Clin Interv Aging; 2007; 2(4):555-60. PubMed ID: 18225455
[TBL] [Abstract][Full Text] [Related]
2. Hemorrhagic cystitis in a patient receiving docetaxel for prostate cancer.
Ntekim AI; Ajekigbe A
Clin Med Insights Oncol; 2010 Apr; 4():11-3. PubMed ID: 20567631
[TBL] [Abstract][Full Text] [Related]
3. Mechanism and Function of Angiogenin in Prostate Cancer.
Vanli N; Guo-Fu HU
Zhongguo Sheng Wu Hua Xue Yu Fen Zi Sheng Wu Xue Bao; 2015 Dec; 31(12):1261-1266. PubMed ID: 27175049
[TBL] [Abstract][Full Text] [Related]
4. PACE4 regulates apoptosis in human prostate cancer cells via endoplasmic reticulum stress and mitochondrial signaling pathways.
Yao Z; Sun B; Hong Q; Yan J; Mu D; Li J; Sheng H; Guo H
Drug Des Devel Ther; 2015; 9():5911-23. PubMed ID: 26604689
[TBL] [Abstract][Full Text] [Related]
5. Drug costs in the management of metastatic castration-resistant prostate cancer in Canada.
Dragomir A; Dinea D; Vanhuyse M; Cury FL; Aprikian AG
BMC Health Serv Res; 2014 Jun; 14():252. PubMed ID: 24927758
[TBL] [Abstract][Full Text] [Related]
6. Low temperature plasma: a novel focal therapy for localized prostate cancer?
Hirst AM; Frame FM; Maitland NJ; O'Connell D
Biomed Res Int; 2014; 2014():878319. PubMed ID: 24738076
[TBL] [Abstract][Full Text] [Related]
7. Drug rechallenge and treatment beyond progression--implications for drug resistance.
Kuczynski EA; Sargent DJ; Grothey A; Kerbel RS
Nat Rev Clin Oncol; 2013 Oct; 10(10):571-87. PubMed ID: 23999218
[TBL] [Abstract][Full Text] [Related]
8. Pleuropulmonary and lymph node progression after docetaxel - benefits from treatment with cabazitaxel in metastatic prostate cancer.
Huerta AS; Santos ER; Campos GB; Coloma CS; Gómez ON
Case Rep Oncol; 2013 May; 6(2):391-6. PubMed ID: 23904851
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of androgen receptor expression with small interfering RNA enhances cancer cell apoptosis by suppressing survival factors in androgen insensitive, late stage LNCaP cells.
Kim SS; Cho HJ; Kang JY; Kang HK; Yoo TK
ScientificWorldJournal; 2013; 2013():519397. PubMed ID: 23476140
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes by relative docetaxel dose and dose intensity as chemotherapy for Japanese patients with castration-resistant prostate cancer: a retrospective multi-institutional collaborative study.
Kamiya N; Suzuki H; Ueda T; Sato N; Nakatsu H; Mikami K; Sato N; Nomura K; Akakura K; Okano T; Ooki T; Naya Y; Ota S; Masai M; Ichikawa T
Int J Clin Oncol; 2014 Feb; 19(1):157-64. PubMed ID: 23299278
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic options for advanced prostate cancer: 2011 update.
Omlin A; de Bono JS
Curr Urol Rep; 2012 Apr; 13(2):170-8. PubMed ID: 22373838
[TBL] [Abstract][Full Text] [Related]
12. Prolonged treatment with three-weekly docetaxel plus daily prednisolone for metastatic castration-resistant prostate cancer: a multicenter, phase II, open-label, non-comparative, extension study in Japan.
Nishimura K; Nonomura N; Hashine K; Kanayama HO; Ozono S; Miura T; Miki T; Kakehi Y; Arai Y; Ogawa O; Fujita R; Nonomura K; Mizokami A; Hoshi S; Akaza H
Int J Clin Oncol; 2013 Apr; 18(2):306-13. PubMed ID: 22350099
[TBL] [Abstract][Full Text] [Related]
13. [Second line therapy for castration-resistant prostate cancer (CRPC)].
Molitor B; Börgermann C
Urologe A; 2012 Mar; 51(3):357-62. PubMed ID: 22113549
[TBL] [Abstract][Full Text] [Related]
14. The changing therapeutic landscape of castration-resistant prostate cancer.
Yap TA; Zivi A; Omlin A; de Bono JS
Nat Rev Clin Oncol; 2011 Aug; 8(10):597-610. PubMed ID: 21826082
[TBL] [Abstract][Full Text] [Related]
15. Current treatment strategies for castration-resistant prostate cancer.
Kim SJ; Kim SI
Korean J Urol; 2011 Mar; 52(3):157-65. PubMed ID: 21461278
[TBL] [Abstract][Full Text] [Related]
16. Guidelines for the management of castrate-resistant prostate cancer.
Saad F; Hotte SJ
Can Urol Assoc J; 2010 Dec; 4(6):380-4. PubMed ID: 21191494
[No Abstract] [Full Text] [Related]
17. Current management of castrate-resistant prostate cancer.
Hotte SJ; Saad F
Curr Oncol; 2010 Sep; 17 Suppl 2(Suppl 2):S72-9. PubMed ID: 20882137
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel chemotherapy for metastatic hormone refractory prostate cancer as first-line palliative chemotherapy and subsequent re-treatment: Birmingham experience.
Ansari J; Hussain SA; Zarkar A; Tanguay JS; Bliss J; Glaholm J
Oncol Rep; 2008 Oct; 20(4):891-6. PubMed ID: 18813832
[TBL] [Abstract][Full Text] [Related]
19. The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer.
Loriot Y; Massard C; Gross-Goupil M; Di Palma M; Escudier B; Bossi A; Chauchereau A; Fizazi K
Eur J Cancer; 2010 Jul; 46(10):1770-2. PubMed ID: 20483588
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
